129 Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma Sham Mailankody, MBBS¹, Jeffrey V. Matous, MD², Michaela Liedtke, MD³, Surbhi Sidana, MD⁴, Shahbaz Malik, MD^5*, Rajneesh Nath, MD⁶, Olalekan O. Oluwole, MBBS, MPH⁷, Erin E. Karski^8*, Wade Lovelace^8*, Xiangdong Zhou, PhD^8*, Srinand Nandakumar, PhD^8*, Arun Balakumaran, MD, PhD⁸ and Parameswaran Hari, MD, MRCP⁹

131 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study Yi Lin, MD, PhD¹, Noopur S. Raje, MD², Jesus G. Berdeja, MD³, David S. Siegel, MD⁴, Sundar Jagannath, MD⁵, Deepu Madduri, MD^5*, Michaela Liedtke, MD⁶, Jacalyn Rosenblatt, MD⁷, Marcela V. Maus, MD, PhD², Monica Massaro, MPH^8*, Fabio Petrocca, MD^9*, Andrea Caia, MS^10*, Zhihong Yang, PhD^10*, Timothy B. Campbell, MD, PhD^10*, Kristen Hege, MD¹⁰, Nikhil C. Munshi, MD¹¹ and James N. Kochenderfer, MD¹²

199 Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA) Navika D Shukla^1*, Alexander F. M. Craig, MPhil², Brian Sworder, MD, PhD¹, David M. Kurtz, MD, PhD¹, Charles Macaulay, MSc, BA^3*, Andrea Garofalo, BS, BA^1*, Matthew J. Frank, MD, PhD⁴, Stefan Alig, MD^1*, George Duran, BA^5*, Youn H. Kim, MD⁶, James Zehnder, MD⁷, Crystal L. Mackall, MD⁸, David B. Miklos, MD, PhD⁴, Maximilian Diehn, MD, PhD^9*, Michael S. Khodadoust, MD, PhD¹⁰ and Ash A. Alizadeh, MD, PhD¹¹

325 Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34⁺ Hematopoietic Stem and Progenitor Cells Amy Fan^1*, Armon Azizi, BS^1*, Kevin Nuno, BS^1*, Yusuke Nakauchi, MD, PhD¹, Feifei Zhao, MD^1*, Andreas Reinisch, MD, PhD^1,2*, David Cruz Hernandez, MS^1,3* and Ravindra Majeti, MD, PhD¹

330 The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results David A. Sallman, MD¹, Adam S. Asch, MD², Suman Kambhampati, MD^3*, Monzr M. Al Malki, MD⁴, Joshua F. Zeidner, MD⁵, William Donnellan, MD⁶, Daniel J. Lee, MD⁷, Paresh Vyas, MRCP, FRCP, FRCPath⁸, Deepa Jeyakumar, MD⁹, Gabriel N. Mannis, MD¹⁰, Tiffany N Tanaka, MD¹¹, Wanxing Chai-Ho, MD¹², Richard A. Larson, MD¹³, Andrew R. Whiteley, MD¹⁴, Guido Marcucci, MD⁴, Rami S. Komrokji, MD¹, Guillermo Garcia-Manero, MD¹⁵, Joanna Van Elk^16*, Ming Lin, PhD^16*, Roy Maute, PhD^16*, Jens-Peter Volkmer, MD^16*, Chris H. Takimoto, MD, PhD^16*, Mark P. Chao, MD, PhD^16* and Naval Daver, MD¹⁵

345 Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study Jason Gotlib, MD, MS¹, Deepti H. Radia, MRCPI, FRCPath^2*, Tracy I. George, MD³, William A Robinson, MD, PhD^4*, Albert T. Quiery, MD⁵, Mark W. Drummond, PhD, FRCPath^6*, Prithviraj Bose, MD⁷, Elizabeth O. Hexner, MD^8*, Elliott F. Winton, MD⁹, Hans-Peter Horny, Prof, Dr^10*, Meera Tugnait, PhD^11*, Oleg Schmidt-Kittler, PhD^11*, Erica K. Evans, PhD^11*, Hui-Min Lin, PhD^11*, Brenton G. Mar, MD, PhD^11*, Michael W. Deininger, MD, PhD¹² and Daniel J. DeAngelo, MD, PhD¹³

975 Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study, Lori S. Muffly, MD¹, Vandana Sundaram, MPH^2*, Connie Chen^3*, Ilana Yurkiewicz, MD, BS⁴, Eric Kuo^5*, Sarah Burnash^3*, Jay Y. Spiegel, MD, FRCPC³, Kelly Chyan^3*, Sally Arai, MD, MS³, Matthew J. Frank, MD, PhD³, Laura J. Johnston, MD³, Robert Lowsky, MD, FRCP³, Everett H Meyer, MD, PhD^3*, Robert S. Negrin, MD³, Andrew R. Rezvani, MD³, Surbhi Sidana, MD⁶, Parveen Shiraz, MD³, Judith A Shizuru, MD, PhD⁷, Wen-Kai Weng, MD, PhD³, Michaela Liedtke, MD⁸, Hyma T. Vempaty, MD⁹ and David B. Miklos, MD, PhD³

1025 V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia Tara Lin, MD1, Gabriel N. Mannis, MD², Harry P. Erba3, Mark Levis, MD, PhD4, Heng Zou5*, Stefan Faderl5, Ronald S. Cheung5 and Vinod A. Pullarkat, MD6

1034 Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All “Non-Adverse” Risk AML Gavin Hui, MD^1*, Abdullah Ladha, MD^2*, Edna Cheung, PharmD^3*, Caroline Berube, MD⁴, Steven Coutre, MD⁴, Jason Gotlib, MD, MS⁴, Michaela Liedtke, MD⁴, Tian Y Zhang, MD, PhD⁴, Lori S. Muffly, MD² and Gabriel N. Mannis, MD⁴

1233 Comparison of the Transcriptomic Signatures in Pediatric and Adult CML Minyoung Youn, PhD^1*, Hee-Don Chae, PhD^1*, Stephanie M. Smith, MD¹, Alex Gia Lee, PhD^2*, Lara C. Murphy, MD^1,3*, Michele Donato, PhD^3,4*, Alejandro Sweet-Cordero^2*, Parveen Abidi, PhD^5*, Henrique Bittencourt, MD, PhD⁶, Norman J. Lacayo, MD¹, Gary Dahl^1*, Catherine Aftandilian, MD¹, Kara L Davis, DO⁷, Jairo A. Matthews^8*, Steven M. Kornblau, MD⁸, Min Huang, PhD^1*, Nathan Sumarsono, BS^1*, Michele Redell, MD⁹, Cecilia H. Fu, MD¹⁰, I-Ming L Chen¹¹, Todd A. Alonzo, PhD^12*, Elizabeth A. Eklund, MD¹³, Jason Gotlib, MD, MS⁵, Purvesh Khatri, PhD^3,4*, Nobuko Hijiya, MD¹⁴ and Kathleen M. Sakamoto, MD, PhD¹

1248 Results from Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent Systemic Mastocytosis Cem Akin, MD, PhD^1*, Hanneke Oude Elberink, MD, PhD^2*, Jason Gotlib, MD, MS³, Vito Sabato, MD, PhD^4*, Karin Hartmann, MD^5*, Sigurd Broesby-Olsen, MD^6*, Mariana Castells, MD, PhD^7*, Tsewang Tashi, MD^8*, Mark L. Heaney, MD⁹, Tracy I. George, MD¹⁰, Frank Siebenhaar, MD^11*, Deepti H. Radia, MRCPI, FRCPath^12*, Massimo Triggiani, MD, PhD^13*, Paul van Daele, MD^14*, Daniel J. DeAngelo, MD, PhD¹⁵, Oleg Schmidt-Kittler, PhD^16*, Hui-Min Lin, PhD^16*, Andrew Morrison, BS^16*, Brenton G. Mar, MD, PhD^16* and Marcus Maurer, MD^11*

1507 Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma Christopher Lemieux, MD¹, Juliana Craig, BA^1*, David Iberri, MD¹, Sally Arai, MD, MS¹, Laura J. Johnston, MD¹, Robert Lowsky, MD, FRCP¹, Lori S. Muffly, MD¹, Parveen Shiraz, MD¹, Michaela Liedtke, MD², Andrew R. Rezvani, MD¹, Matthew J. Frank, MD, PhD¹, Wen-Kai Weng, MD, PhD¹, Everett H Meyer, MD, PhD^1*, Judith A Shizuru, MD, PhD¹, Robert S. Negrin, MD¹, David B. Miklos, MD, PhD¹ and Surbhi Sidana, MD¹

1526 Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia Vanessa E Kennedy, MD¹, Gavin Hui, MD^2*, Daria Gaut, MD³, Varun Mittal, MD⁴, Caspian Oliai, M.D.⁵, Lori S. Muffly, MD⁶, Aaron C. Logan, MD, PhD, MPhil⁷ and Gabriel N. Mannis, MD⁸

1614 The Value of an Embedded Outpatient Palliative Care Program in Malignant Hematology: Concurrent Care and the Impact on Health Care Utilization Mazie Tsang, MD¹, Kelly L. Schoenbeck, MD², Kim Berry, MBA^3*, Eve Cohen, RN^4*, Kara Bischoff, MD^4*, Nancy Shepard Lopez, NP^4*, Gabriel N. Mannis, MD⁵ and Michael Rabow, MD, FAAHPM^4*

1788 Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity Andrew Johnsrud, MD¹, Juliana Craig, BA^1*, John H. Baird, MD^1,2, Jay Y. Spiegel, MD, FRCPC¹, Lori S. Muffly, MD³, James Zehnder, MD⁴, Robert S. Negrin, MD¹, Laura J. Johnston, MD¹, Sally Arai, MD, MS¹, Judith A Shizuru, MD, PhD¹, Robert Lowsky, MD, FRCP¹, Everett H Meyer, MD, PhD^1*, Wen-Kai Weng, MD, PhD¹, Parveen Shiraz, MD¹, Andrew R. Rezvani, MD¹, Theresa Latchford, RN^1*, Crystal L. Mackall, MD⁵, David B. Miklos, MD, PhD¹, Matthew J. Frank, MD, PhD¹ and Surbhi Sidana, MD⁶

2000 Clonal Architecture and Variant Allele Frequency Predict Clinical Outcomes and Drug Response in Acute Myeloid Leukemia Brooks Benard, BS^1,2*, Logan Leak, BS^1,3*, Armon Azizi, BS^2*, Daniel Thomas, MD, PhD⁴, Andrew Gentles, PhD^5* and Ravi Majeti, MD, PhD²

2219 Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials John N. Allan, MD¹, Tait Shanafelt, MD², Adrian Wiestner, MD, PhD^3*, Carol Moreno, MD, PhD^4*, Susan M. O'Brien, MD⁵, Esteban Braggio, PhD⁶, Emily Liu, MS^7*, James P. Dean, MD, PhD⁷, Dominic Lai, PharmD^7* and Inhye E. Ahn, MD³

2446 Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients José Luis López Lorenzo, MD^1,2*, Susana Navarro, PhD^2,3,4*, Ami J Shah, MD^5,6,7, Maria Grazia Roncarolo, MD^5,6,7, Julián Sevilla, MD, PhD^8*, Lucía Llanos, MD, PhD^1,2*, Begoña Pérez Camino de Gaisse, MD^1,2*, Sol Sanchez, MD^1,2*, Bertil Glader, MD, PhD^7,9, May Chien, MD^7,9, Oscar Quintana Bustamante, PhD^2,3,4*, Brian C Beard, PhD^10*, Kenneth M Law, PhD^10*, Miriam Zeini, PhD^10*, Grace Choi, BS^10*, Eileen Nicoletti, MD^10*, Juan A Bueren, PhD^2,3,4*, Gayatri R Rao, MD, JD^10*, Jonathan D Schwartz, MD¹⁰ and José C Segovia, PhD^2,3,4*

2765 Multi-Omic Analysis Identifies Epigenetic Evolution in Relapsed Acute Myeloid Leukemia Kevin Nuno, BS^1*, Armon Azizi, BS^1*, Thomas Koehnke, MD¹, M. Ryan Corces, PhD^2,3 and Ravi Majeti, MD, PhD¹

2871 Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting Rebecca M Richards, MD, PhD¹, Feifei Zhao^2*, Katherine A Murphy^3*, Peng Xu, MD^4*, Amy Fan^5*, Elena Sotillo, PhD^6*, Mads Daugaard^7*, Htoo Zarni Oo^7*, Jie Liu^8*, Wan-Jen Hong⁹, Poul Sorensen^10*, Robbie G. Majzner, MD⁶, Ravi Majeti, MD, PhD¹¹ and Crystal L. Mackall, MD¹²

2988 Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis Cem Akin, MD, PhD^1*, Hanneke Oude Elberink, MD, PhD^2*, Jason Gotlib, MD, MS³, Vito Sabato, MD, PhD^4*, Karin Hartmann, MD^5*, Sigurd Broesby-Olsen, MD^6*, Mariana Castells, MD, PhD^7*, Tsewang Tashi, MD^8*, Mark L. Heaney, MD⁹, Tracy I. George, MD¹⁰, Frank Siebenhaar, MD^11*, Deepti H. Radia, MRCPI, FRCPath^12*, Massimo Triggiani, MD, PhD^13*, Paul van Daele, MD^14*, Daniel J. DeAngelo, MD, PhD¹⁵, Iván Alvarez-Twose, MD, PhD^16*, Andreas Reiter, MD^17*, Peter Vadas, MD, PhD^18*, Patrizia Bonadonna, MD^19*, Paggy Hew, MS^20*, Hui-Min Lin, PhD^21*, Maria Roche, MS^20* and Marcus Maurer, MD^11*

2992 Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) – Updated Data from the Phase 2 ACE-536-MF-001 Study Aaron T. Gerds, MD, MS1, Alessandro M. Vannucchi, MD 2, Francesco Passamonti3*, Marina Kremyanskaya4, Jason Gotlib, MD MS5*, Jeanne M. Palmer, Md6, Kelly McCaul7*, Vincent Ribrag, MD8, Adam J. Mead, MD, PhD9, Claire Harrison, DM, FRCP, FRCPath10, Ruben Mesa, MD11, Jean-Jacques Kiladjian12, Giovanni Barosi13, Torsten G. Gerike14*, Jeevan K. Shetty15*, Joseph Pariseau14*, Gabriel Miranda14*, Martin Schwickart14*, Ana Carolina Giuseppi14*, Jennie Zhang14*, Jay T. Backstrom16* and Srdan Verstovsek, MD, PhD17

3000 A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104) Stephen T. Oh, MD¹, Jason Gotlib, MD, MS², Sanjay Mohan, MD, MSCI³, Haris Ali, MD⁴, Ekatherine Asatiani, MD⁵, Francis Seguy^5*, Feng Zhou^6* and Srdan Verstovsek, MD, PhD⁷

3111 Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study Rami S. Komrokji, MD¹, Uwe Platzbecker, MD², Pierre Fenaux, MD, PhD³, Guillermo Garcia-Manero, MD⁴, Ghulam J. Mufti, Professor^5*, Valeria Santini^6*, Maria Diez-Campelo, PhD, MD^7*, Carlo Finelli^8*, Joseph G. Jurcic, MD⁹, Peter L. Greenberg¹⁰, Mikkael A. Sekeres¹¹, Amer M. Zeidan, MBBS, MHS¹², Amy E. DeZern, MD¹³, Michael R. Savona, MD¹⁴, Jeevan K. Shetty^15*, Rodrigo Ito^16*, George Zhang^16*, Xianwei Ha^16*, Daniel Sinsimer^16*, Jay T. Backstrom^17* and Amit Verma, MBBS¹⁸

3117 Correlating Clinical and Genomic Features with Ex Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms Michael A Spinner, MD¹, Steven A Schaffert, PhD^2*, Alexey Aleshin, MD, MBA³, Marianne T Santaguida, PhD^2*, Hiroomi Tada, MD PhD² and Peter L. Greenberg³

3132 Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes Geffen Kleinstern, PhD¹, J. Brice Weinberg, MD^2,3,4,5, Sameer A. Parikh, MD⁶, Esteban Braggio, PhD⁷, Dennis P. Robinson^8*, Aaron D. Norman, MPH^8*, Kari G Rabe^8*, Celine M. Vachon, PhD⁹, Connie E. Lesnick^8*, Timothy G. Call, MD⁶, Danielle M. Brander, MD^10,11, Janet E. Olson, PhD^8*, James R. Cerhan, MD, PhD⁸, Neil E. Kay, MD⁶, Curtis A. Hanson, MD^6*, Richard R. Furman, MD^12,13, Tait Shanafelt, MD¹⁴ and Susan L. Slager, PhD¹

3169 Response Evaluation Using PET/CT in Multiple Myeloma Patients Undergoing Autologous Transplant, Tim Ellis-Caleo, MD^1*, Surbhi Sidana, MD², Michaela Liedtke, MD³ and David Iberri, MD³

3211 Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma, Karthik Ramasamy¹, Ajay Nooka, MD, MPH², Hang Quach, MD, FRACP, FRCPA, MBBS³, Myo Htut, MD⁴, Rakesh Popat^5*, Michaela Liedtke, MD⁶, Sascha A Tuchman, MD⁷, Jacob P. Laubach, MD⁸, Cristina Gasparetto, MD⁹, Asher A. Chanan-Khan, MD¹⁰, Mark Hertzberg, MBBS PhD FRACP FRCPA¹¹, Mark Demario, MD, MPH^12*, Eveline Nueesch, PhD^13*, Evelyne Chesne, PhD^13*, Izolda Franjkovic, PhD^14*, Katharina Lechner^14*, Martin Kornacker, MD¹³ and Hearn Jay Cho, MD, PhD¹⁵

Session: Friend or Foe: The Microbiome, Antibiotics and Death After Transplant

·       Ami S. Bhatt, MD, PhD - Basic Biology of the Microbiome Universe

Session: Plenary Scientific Session

·       Ravi Majeti, MD, PhD - Plenary Introducer